BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 19685204)

  • 1. Infliximab treatment reduces the serum levels of interleukin-23 in patients with rheumatoid arthritis.
    Kageyama Y; Kobayashi H; Kato N
    Mod Rheumatol; 2009; 19(6):657-62. PubMed ID: 19685204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modification of pro- and antiinflammatory cytokines and vascular-related molecules by tumor necrosis factor-a blockade in patients with rheumatoid arthritis.
    Macías I; García-Pérez S; Ruiz-Tudela M; Medina F; Chozas N; Girón-González JA
    J Rheumatol; 2005 Nov; 32(11):2102-8. PubMed ID: 16265686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of serum chemokines following infliximab therapy in patients with rheumatoid arthritis.
    Klimiuk PA; Sierakowski S; Domyslawska I; Chwiecko J
    Clin Exp Rheumatol; 2006; 24(5):529-33. PubMed ID: 17181921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial.
    Quinn MA; Conaghan PG; O'Connor PJ; Karim Z; Greenstein A; Brown A; Brown C; Fraser A; Jarret S; Emery P
    Arthritis Rheum; 2005 Jan; 52(1):27-35. PubMed ID: 15641102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum levels of lipoprotein(a) and E-selectin are reduced in rheumatoid arthritis patients treated with methotrexate or methotrexate in combination with TNF-α-inhibitor.
    Hjeltnes G; Hollan I; Førre O; Wiik A; Lyberg T; Mikkelsen K; Agewall S
    Clin Exp Rheumatol; 2013; 31(3):415-21. PubMed ID: 23465067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum proteomic analysis identifies interleukin 16 as a biomarker for clinical response during early treatment of rheumatoid arthritis.
    Murota A; Suzuki K; Kassai Y; Miyazaki T; Morita R; Kondo Y; Takeshita M; Niki Y; Yoshimura A; Takeuchi T
    Cytokine; 2016 Feb; 78():87-93. PubMed ID: 26700586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.
    Maini RN; Breedveld FC; Kalden JR; Smolen JS; Davis D; Macfarlane JD; Antoni C; Leeb B; Elliott MJ; Woody JN; Schaible TF; Feldmann M
    Arthritis Rheum; 1998 Sep; 41(9):1552-63. PubMed ID: 9751087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in biomarkers of inflammation and bone turnover and associations with clinical efficacy following infliximab plus methotrexate therapy in patients with early rheumatoid arthritis.
    Visvanathan S; Marini JC; Smolen JS; Clair EW; Pritchard C; Shergy W; Pendley C; Baker D; Bala M; Gathany T; Han J; Wagner C
    J Rheumatol; 2007 Jul; 34(7):1465-74. PubMed ID: 17552048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. E-selectin, interleukin 18, serum amyloid a, and matrix metalloproteinase 9 are associated with clinical response to golimumab plus methotrexate in patients with active rheumatoid arthritis despite methotrexate therapy.
    Visvanathan S; Wagner C; Rojas J; Kay J; Dasgupta B; Matteson EL; Mack M; Baker DG; Rahman MU
    J Rheumatol; 2009 Jul; 36(7):1371-9. PubMed ID: 19487269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Multi-Biomarker Disease Activity Score and the Choice of Second-Line Therapy in Early Rheumatoid Arthritis After Methotrexate Failure.
    Hambardzumyan K; Saevarsdottir S; Forslind K; Petersson IF; Wallman JK; Ernestam S; Bolce RJ; van Vollenhoven RF
    Arthritis Rheumatol; 2017 May; 69(5):953-963. PubMed ID: 27992691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment with infliximab plus methotrexate improves anemia in patients with rheumatoid arthritis independent of improvement in other clinical outcome measures-a pooled analysis from three large, multicenter, double-blind, randomized clinical trials.
    Doyle MK; Rahman MU; Han C; Han J; Giles J; Bingham CO; Bathon J
    Semin Arthritis Rheum; 2009 Oct; 39(2):123-31. PubMed ID: 18823645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infliximab is associated with improvement in arterial stiffness in patients with early rheumatoid arthritis -- a randomized trial.
    Tam LS; Shang Q; Li EK; Wang S; Li RJ; Lee KL; Leung YY; Ying KY; Yim CW; Kun EW; Leung MH; Li M; Li TK; Zhu TY; Chui RK; Tseung L; Yu SL; Kuan WP; Yu CM
    J Rheumatol; 2012 Dec; 39(12):2267-75. PubMed ID: 22984272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and validation of handy rheumatoid activity score with 38 joints (HRAS38) in rheumatoid arthritis patients receiving infliximab.
    Kameda H; Sekiguchi N; Nagasawa H; Amano K; Takei H; Suzuki K; Nishi E; Ogawa H; Takeuchi T
    Mod Rheumatol; 2006; 16(6):381-8. PubMed ID: 17165001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Baseline Serum Osteopontin Levels Predict the Clinical Effectiveness of Tocilizumab but Not Infliximab in Biologic-Naïve Patients with Rheumatoid Arthritis: A Single-Center Prospective Study at 1 Year (the Keio First-Bio Cohort Study).
    Izumi K; Kaneko Y; Hashizume M; Yoshimoto K; Takeuchi T
    PLoS One; 2015; 10(12):e0145468. PubMed ID: 26698858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Requirement of methotrexate in combination with anti-tumor necrosis factor-alpha therapy for adequate suppression of osteoclastogenesis in rheumatoid arthritis.
    Matsuno H; Yoshida K; Ochiai A; Okamoto M
    J Rheumatol; 2007 Dec; 34(12):2326-33. PubMed ID: 18050387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Sanhuangyilong decoction plus methotrexate on tumor necrosis factor alpha and interferon gamma in serum and synovial fluid in rheumatoid arthritis patients with symptom pattern of damp heat obstruction.
    Liu D; Yan J; Yun M; Yang M; Luo Y; Zhang J; Guo M; Yang M; Yuan W; Zou W; Li H; Hu Y
    J Tradit Chin Med; 2016 Oct; 36(5):625-33. PubMed ID: 29933531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis.
    Kapetanovic MC; Saxne T; Sjöholm A; Truedsson L; Jönsson G; Geborek P
    Rheumatology (Oxford); 2006 Jan; 45(1):106-11. PubMed ID: 16287919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methotrexate dosage reduction in patients with rheumatoid arthritis beginning therapy with infliximab: the Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) trial.
    Fleischmann RM; Cohen SB; Moreland LW; Schiff M; Mease PJ; Smith DB; Keenan G; Kremer JM;
    Curr Med Res Opin; 2005 Aug; 21(8):1181-90. PubMed ID: 16083527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Addition of another disease-modifying anti-rheumatic drug to methotrexate reduces the flare rate within 2 years after infliximab discontinuation in patients with rheumatoid arthritis: an open, randomized, controlled trial.
    Kurasawa T; Nagasawa H; Kishimoto M; Amano K; Takeuchi T; Kameda H
    Mod Rheumatol; 2014 Jul; 24(4):561-6. PubMed ID: 24252035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum interleukin 6 before and after therapy with tocilizumab is a principal biomarker in patients with rheumatoid arthritis.
    Shimamoto K; Ito T; Ozaki Y; Amuro H; Tanaka A; Nishizawa T; Son Y; Inaba M; Nomura S
    J Rheumatol; 2013 Jul; 40(7):1074-81. PubMed ID: 23637318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.